Has Anisha Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $64,262 in general payments to Anisha Patel, MD across 83 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anisha Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anisha Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anisha Patel, MD

Dermatology · Houston, TXNPI 1972764942

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $39,008 of the $64,262 with a category attached, or 60.7%. 15 manufacturers reported payments, led by Chugai Pharmaceutical Co., Ltd. at 28.9% of the total. Reporting peaked in 2024 at $25,182 and has fallen 86.8% since, to $3,334 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,262in general payments, 2019–2025

Across 83 payments — averaging $774.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Chugai Pharmaceutical Co., Ltd.$19K
Novartis$13K
Incyte Corporation$10K
Janssen Scientific Affairs, LLC$8K
Pfizer$5K
Deciphera Pharmaceuticals Inc.$5K
plus $4K from 9 others

$300,256in research payments, 2019–2025

Across 50 payments — averaging $6005.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$194K
Onquality Pharmaceuticals (USA) LLC$88K
Incyte Corporation$13K
Novartis$5K

What the payments were for

Consulting fees$39,00861%
Speaking & faculty fees$4,2937%
Travel & lodging$18,50429%
Food & beverage$2,4574%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Chugai Pharmaceutical Co., Ltd.	3	$18,565
Novartis	8	$12,665
Incyte Corporation	17	$10,274
Janssen Scientific Affairs, LLC	11	$8,477
Pfizer	7	$5,495
Deciphera Pharmaceuticals Inc.	1	$4,900
Bayer	4	$1,931
Janssen Global Services, LLC	1	$800
Bard Peripheral Vascular, Inc.	19	$379
Dermavant Sciences, Inc.	5	$306
Johnson & Johnson	2	$194
LEO Pharma Inc.	1	$127
Regeneron	2	$92
AstraZeneca	1	$52
Biofrontera Inc.	1	$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OPZELURA$9,878
BYL719$6,464
BRAFTOVI$3,700
MEKTOVI$3,700
RYBREVANT$2,624
Nexavar$1,824
PIQRAY$412
VTAMA$249
ADBRY$127
NA$117

How this compares

$64,262 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas →

Medicare billing

Part B allowed, 2024

$186,077

Medicare patients

1,398

Services billed

3,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	30	$133,285
Acitretin	25	$9,437
Betamethasone Dipropionate	50	$2,193
Dapsone	12	$819
Fluorouracil	18	$777
Triamcinolone Acetonide	57	$715
Econazole Nitrate	19	$703
Metronidazole	15	$642
Doxycycline Hyclate	22	$596
Clobetasol Propionate	20	$506
Hydroxyzine Hcl	22	$394
Ketoconazole	25	$390
Nystatin	11	$371
Clindamycin Phosphate	13	$338
Hydrocortisone	56	$328

Paid to pharmacies, not to this prescriber.

Other dermatology in Houston

Alpesh DesaiHouston$1.6M
Geeta PatelHouston$575K
Michael MigdenHouston$310K
Catherine PapasakelariouHouston$289K
Stephen MahoneyHouston$137K
Edward LainAustin$2.5M
William CragunSan Antonio$2.2M
Craig TellerBellaire$1.3M
Jennifer CatherDallas$1.3M
Emily BeckerSan Antonio$1.2M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →